Common Cold News and Research

RSS

UC San Diego participates in second, massive clinical trial of COVID-19 vaccine

UC San Diego Health will be part of a second, massive clinical trial to assess the safety, efficacy and immunogenicity of a vaccine designed to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

2 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Interventions can successfully reduce the rate of inappropriate antibiotic prescriptions

Two different interventions both worked to significantly reduce the rate of inappropriate antibiotic prescriptions made by physicians in a telemedicine practice, a new study led by Children's National Hospital researchers shows.

27 Aug 2020

World's first confirmed case of SARS-CoV-2 re-infection

A team of researchers at the University of Hong Kong said that they have proven that a 33-year-old man was infected by the SARS-CoV-2 virus for a second time. The man was discharged from a hospital in April but contracted the infection again after returning from Spain via the United Kingdom in August.

24 Aug 2020

Single dose nasal vaccine against SARS-CoV-2 shows promise in animal studies

Now researchers at the Washington University School of Medicine in St. Louis have worked on developing a candidate vaccine against the infection that could be administered in a single dose via a nasal spray rather than an injection. In their preliminary studies using lab mice, this single dose of the nasal vaccine successfully prevented the infection with the novel coronavirus.

24 Aug 2020

Research suggests seaweed extract and xylitol may help protect against COVID-19

Researchers in the United States have demonstrated the antiviral effect of three candidate nasal spray formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

24 Aug 2020

New cancer vaccine is predicted to be more effective in human trials

Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.

24 Aug 2020

Nasal vaccine effective in preventing COVID-19 infection in mice

Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

Children play a larger role in the community spread of COVID-19 than previously thought

In the most comprehensive study of COVID-19 pediatric patients to date, Massachusetts General Hospital (MGH) and Mass General Hospital for Children (MGHfC) researchers provide critical data showing that children play a larger role in the community spread of COVID-19 than previously thought

20 Aug 2020

Research shows how smell loss linked to Covid-19 differs from the common cold

New research from a European group of smell disorder experts, including Prof Philpott at the University of East Anglia, shows how smell loss associated with Covid-19 infection differs from what you typically might experience with a bad cold or flu.

18 Aug 2020

Study shows coronavirus thrives in dry air with low humidity

A new study by researchers from the University of Sydney and the Fudan University School of Public Health in Shanghai suggests that low humidity increases the risk of spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Aug 2020

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Study shows home monitoring program improves survival rates in infants with heart defects

Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.

11 Aug 2020

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

CDC warns acute flaccid myelitis is poised for a comeback in kids this fall

As if the novel coronavirus pandemic was not enough! Now the United States Centre for Disease Control and Prevention (CDC) warns parents and pediatricians to be on the watch for a rare condition called Acute Flaccid Myelitis or AFM for short, which could affect young children and cause unexplained muscle paralysis similar to poliomyelitis. Their report is published today in the Morbidity and Mortality Weekly Report.

5 Aug 2020

Study: "Memory" T cells that recognize common cold coronaviruses also recognize SARS-CoV-2

Your immune system's "memory" T cells keep track of the viruses they have seen before. This immune cell memory gives the cells a headstart in recognizing and fighting off repeat invaders.

5 Aug 2020

Pre-COVID-19 coronavirus antibodies fail to neutralize SARS-CoV-2

Researchers in Austria have shown that antibodies with potent neutralizing activity against a well-established seasonal coronavirus had no neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2020

Novel vaccine candidate robustly protects non-human primates against SARS-CoV-2

The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.

30 Jul 2020

Relatives of SARS-CoV-2 may pose a health threat for years to come

Coronaviruses are zoonotic viruses that jump from animals to humans and cause infection. There are many types of common human coronaviruses, which usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. Most people get infected with one or more of coronavirus types 229E, NL63, OC43, and HKU1 at some point in their lives.

29 Jul 2020